LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes

Diabetologia

Volumn 59, Issue 3, 2016, Pages 634-643

  Cannon, Megan V ^a   Silljé, Herman H W ^a   Sijbesma, Jürgen W A ^a   Khan, Mohsin A F ^a   Steffensen, Knut R ^b   van Gilst, Wiek H ^a   de Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetic cardiomyopathy; Left ventricular hypertrophy; Liver X receptor; Natriuretic peptides

Indexed keywords

5 ' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; LIVER X RECEPTOR ALPHA; NATRIURETIC FACTOR; PROTEIN KINASE; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LIVER X RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENERGY; GENE OVEREXPRESSION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID DIET; LOW FAT DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; GENETICS; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARDIOMEGALY; CHROMATIN IMMUNOPRECIPITATION; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; LIVER X RECEPTORS; MICE; MICE, TRANSGENIC; MYOCARDIUM; OBESITY;

EID: 84957430188     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3827-x     Document Type: Article

References (39)

1. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L (2005) Insulin resistance and risk of congestive heart failure. JAMA 294:334–341
2. Woodiwiss AJ, Libhaber CD, Majane OH, Libhaber E, Maseko M, Norton GR (2008) Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 21:1144–1151
3. Galderisi M, Anderson KM, Wilson PW, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68:85–89
4. Taegtmeyer H, McNulty P, Young ME (2002) Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105:1727–1733
5. Cao G, Liang Y, Broderick CL et al (2003) Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131–1136
6. Liu Y, Yan C, Wang Y et al (2006) Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147:5061–5068
7. Laffitte BA, Chao LC, Li J et al (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 100:5419–5424
8. Grefhorst A, van Dijk TH, Hammer A et al (2005) Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 289:E829–E838
9. Baranowski M, Zabielski P, Blachnio-Zabielska AU, Harasim E, Chabowski A, Gorski J (2014) Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation. Cell Physiol Biochem 33:1047–1057
10. Patel M, Wang XX, Magomedova L et al (2014) Liver X receptors preserve renal glomerular integrity under normoglycaemia and in diabetes in mice. Diabetologia 57:435–446
11. Wu S, Yin R, Ernest R et al (2009) Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 84:119–126
12. Kuipers I, Li J, Vreeswijk-Baudoin I et al (2010) Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail 12:1042–1050
13. Cannon MV, Yu H, Candido WM et al (2015) The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Eur J Heart Fail 17:273–282
14. Lei P, Baysa A, Nebb HI et al (2013) Activation of liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury. Basic Res Cardiol 108:323
15. He Q, Pu J, Yuan A et al (2014) Activation of liver-X-receptor alpha but not liver-X-receptor beta protects against myocardial ischemia/reperfusion injury. Circ Heart Fail 7:1032–1041
16. He Q, Pu J, Yuan A et al (2014) Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice. Cardiovasc Diabetol 13:149
17. Cannon MV, Sillje HH, Sijbesma JW et al (2015) Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med 7:1229–1243
18. Yu L, Ruifrok WP, Meissner M et al (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6:107–117
19. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318–328
20. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP (2014) Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol 11:403–412
21. Commerford SR, Vargas L, Dorfman SE et al (2007) Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol 21:3002–3012
22. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602
23. Ouwens DM, Boer C, Fodor M et al (2005) Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 48:1229–1237
24. Gupte AA, Minze LJ, Reyes M et al (2013) High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance. Endocrinology 154:2650–2662
25. Ohtake T, Yokoyama I, Watanabe T et al (1995) Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 36:456–463
26. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG (2002) Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 51:3020–3024
27. Griesel BA, Weems J, Russell RA, Abel ED, Humphries K, Olson AL (2010) Acute inhibition of fatty acid import inhibits GLUT4 transcription in adipose tissue, but not skeletal or cardiac muscle tissue, partly through liver X receptor (LXR) signaling. Diabetes 59:800–807
28. Sung MM, Koonen DP, Soltys CL, Jacobs RL, Febbraio M, Dyck JR (2011) Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction. J Mol Med (Berl) 89:459–469
29. Koonen DP, Febbraio M, Bonnet S et al (2007) CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 116:2139–2147
30. Welsh P, McMurray JJ (2012) B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia 55:1240–1243
31. Holtwick R, van Eickels M, Skryabin BV et al (2003) Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111:1399–1407
32. Franco V, Chen YF, Oparil S et al (2004) Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 44:746–750
33. Rubattu S, Bigatti G, Evangelista A et al (2006) Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48:499–505
34. Wang TJ, Larson MG, Levy D et al (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109:594–600
35. Olsen MH, Hansen TW, Christensen MK et al (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46:660–666
36. Gutkowska J, Broderick TL, Bogdan D, Wang D, Lavoie JM, Jankowski M (2009) Downregulation of oxytocin and natriuretic peptides in diabetes: possible implications in cardiomyopathy. J Physiol 587:4725–4736
37. Plante E, Menaouar A, Danalache BA, Broderick TL, Jankowski M, Gutkowska J (2014) Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. Diabetologia 57:1257–1267
38. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH (2003) B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP. Diabetes 52:2389–2395
39. McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004